Jack Howell and Luke Taylor Named Co-Presidents of Stonepeak
NEW YORK–(BUSINESS WIRE)–Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, today announced that Jack Howell... Read more.
Terran Orbital Receives Payment from Rivada
BOCA RATON, Fla.–(BUSINESS WIRE)–#aerospace–Terran Orbital Corporation (NYSE: LLAP) (“Terran Orbital” or the “Company”), a global leader... Read more.
FREYR Battery Completes Redomicile from Luxembourg to the U.S.
NEW YORK, OSLO, and NEWNAN, Ga.–(BUSINESS WIRE)–FREYR Battery, Inc. (NYSE: FREY) (“FREYR” or the “Company”), a developer of clean, next-generation... Read more.
Global Spatial Computing Market – In-depth Analysis through 2028 with Focus on AR, VR, MR, IoT, and AI Technologies – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Spatial Computing Market” report has been added to ResearchAndMarkets.com’s offering. The report... Read more.
Anaergia Announces Strategic Investment Update
BURLINGTON, Ontario–(BUSINESS WIRE)–Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG), a global renewable fuels leader, is pleased to announce... Read more.
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
Up to $300 million non-dilutive capital exchanged for royalty payments on future ImmunityBio immunotherapy product revenue with up to a $20 million equity investment... Read more.
Quality Collision Group Strengthens National Presence With Acquisition of Utah-Based MSO, Cascade Collision Repair
CHADDS FORD, Pa.–(BUSINESS WIRE)–Quality Collision Group (QCG), a leading syndicate of OEM-certified collision repair centers, proudly announces the... Read more.
Diakonos Oncology Completes Phase 1 Glioblastoma Trial Recruitment; Receives FDA Orphan Drug Designation
HOUSTON–(BUSINESS WIRE)–Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today it has completed enrollment... Read more.
Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate
The 25 valent pneumococcal conjugate vaccine is designed to broaden protection against life-threatening childhood pneumonia and other serious pneumococcal diseases.... Read more.
Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout
ABP-745 is an oral small molecule drug that also has potential applications for other anti-inflammatory diseases JIANGSU, China–(BUSINESS WIRE)–Atom... Read more.